PDCD1 and non-small cell lung carcinoma: The DNA methyltransferase (DNMT) inhibitor decitabine demonstrates synergistic efficacy with PD-1 inhibitors (e.g., camrelizumab) in advanced NSCLC by reversing PD-1 promoter hypermethylation[129,130].